-Over 100 emerging biotech companies adopt Veeva Basics to simplify and standardize their operations
New Apps Like Veeva LIMS Basics and PromoMats Basics Drive Speed and Growth
/PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that more than 100 biotechnology companies have chosen Veeva Basics to optimize their operations in clinical, regulatory and quality areas. A growing number of biotechnology companies in the United States and Europe are laying the foundation for their growth with a simple, standardized, industry-leading solution that adapts to changing business needs.
With Veeva Basics, biotech companies leverage industry-leading applications, pre-configured and validated for rapid deployment. Veeva Basics is built on the Vault platform, allowing biotech companies to move to a full Vault solution without the need for migration. This provides businesses with the technology and support needed to achieve efficient processes in key areas of the business, both now and in the long term.
“More than 100 biotech leaders from 60 companies gathered at the Veeva R&D and Quality Summit in Boston to learn, connect and define the future of Veeva Basics. “We are proud of the impact Veeva Basics is having on emerging biotechnology companies and will continue to introduce innovative new applications that can be rapidly deployed to support the development of new medicines,” said Steve Harper, CEO of Veeva Basics.
To meet critical quality control (QC) and business needs, Veeva Basics introduces two new applications:
- Veeva LIMS Basics for virtual enterprises that enables chief marketing officer (CMO) oversight, including batch release and certificate of analysis (CoA) generation. Stability functionality planned for 2026.
- Veeva PromoMats Basics for end-to-end content lifecycle management, including approval, storage and distribution of promotional content, as well as claims management.
Veeva LIMS (laboratory information management) Basics and PromoMats Basics are expected to be available in early 2026. Based on the proven Vault platform, Veeva Basics applications help customers scale their technology infrastructure as they grow. For more information about Veeva Basics, visit veevabasics.com.
Opinions of biotech companies on Veeva Basics:
“As a rapidly growing company, we understood the value of Veeva Basics in standardizing our processes to industry best practices. Knowing that we have an agile solution that works now, while providing us with easy access to the Veeva Vault platform as we grow, gives us peace of mind that we can meet future needs,” explained Richard Tornai, Senior IT Director of Clinical R&D at Structure Therapeutics.
“Laying the foundation for our quality and compliance operations was a priority for us, and we needed a cost-effective and compliant solution for document and records management. We believe Veeva Basics meets these needs and more by providing logical workflows, a library of SOP templates and forms, and simple, effective training,” said Bryan Ball, Director of Technical Operations at Whitehawk Therapeutics.
“Veeva Basics offered us a cutting-edge solution with global support to quickly train our staff. Veeva’s commitment to innovation for biotech companies and its focus on customer success make it the ideal partner,” said Bernhard Irlinger, Quality Manager at AiCuris.
About Veeva Systems
Veeva delivers the industrial cloud for life sciences with software, data and business consulting. Committed to innovation, product excellence and customer success, Veeva serves more than 1,500 customers, from the world’s largest biopharmaceutical companies to emerging biotechnology companies. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all of its stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva products and services and the expected results or benefits derived from their use. These statements are based on our current expectations. Actual results could differ materially from those indicated in this release and we undertake no obligation to update such statements. There are numerous risks that could adversely affect our results, including the risks and uncertainties disclosed in our quarterly report (Form 10-Q) for the period ended July 31, 2025, which can be found here (a summary of the risks that could affect our business is available on pages 33 and 34), and in our subsequent reports filed with the SEC, which can be accessed at sec.gov.
Contact:
Jeremy Whittaker
Veeva Systems
+49-695-095-5486
[emailprotected]
Logo -https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo_v2.jpg